The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.
G. Oskay-Ă–zcelik
No relevant relationships to disclose
R. Richter
No relevant relationships to disclose
K. Pietzner
No relevant relationships to disclose
H. Hindenburg
No relevant relationships to disclose
H. L. Sommer
No relevant relationships to disclose
R. Chekerov
No relevant relationships to disclose
O. Camara
No relevant relationships to disclose
E. Keil
No relevant relationships to disclose
J. Einenkel
No relevant relationships to disclose
W. Lichtenegger
No relevant relationships to disclose
J. Sehouli
No relevant relationships to disclose